A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Descamps, G, Gomez-Bougie, P, Venot, C, Moreau, P, Bataille, R, Amiot, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634719/
https://www.ncbi.nlm.nih.gov/pubmed/19165200
http://dx.doi.org/10.1038/sj.bjc.6604839
_version_ 1782164151082156032
author Descamps, G
Gomez-Bougie, P
Venot, C
Moreau, P
Bataille, R
Amiot, M
author_facet Descamps, G
Gomez-Bougie, P
Venot, C
Moreau, P
Bataille, R
Amiot, M
author_sort Descamps, G
collection PubMed
description The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45(neg) Myeloma patients, particularly those with the most aggressive form, t(4,14).
format Text
id pubmed-2634719
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-26347192010-01-27 A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45 Descamps, G Gomez-Bougie, P Venot, C Moreau, P Bataille, R Amiot, M Br J Cancer Molecular Diagnostics The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45(neg) Myeloma patients, particularly those with the most aggressive form, t(4,14). Nature Publishing Group 2009-01-27 2009-01-22 /pmc/articles/PMC2634719/ /pubmed/19165200 http://dx.doi.org/10.1038/sj.bjc.6604839 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Descamps, G
Gomez-Bougie, P
Venot, C
Moreau, P
Bataille, R
Amiot, M
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
title A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
title_full A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
title_fullStr A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
title_full_unstemmed A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
title_short A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
title_sort humanised anti-igf-1r monoclonal antibody (ave1642) enhances bortezomib-induced apoptosis in myeloma cells lacking cd45
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634719/
https://www.ncbi.nlm.nih.gov/pubmed/19165200
http://dx.doi.org/10.1038/sj.bjc.6604839
work_keys_str_mv AT descampsg ahumanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT gomezbougiep ahumanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT venotc ahumanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT moreaup ahumanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT batailler ahumanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT amiotm ahumanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT descampsg humanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT gomezbougiep humanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT venotc humanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT moreaup humanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT batailler humanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45
AT amiotm humanisedantiigf1rmonoclonalantibodyave1642enhancesbortezomibinducedapoptosisinmyelomacellslackingcd45

Ejemplares similares